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Natural cytotoxicity receptors (NCRs) have been classically defined as activating receptors
delivering potent signals to Natural Killer (NK) cells in order to lyze harmful cells and to
produce inflammatory cytokines. Indeed, the elicitation of NK cell effector functions after
engagement of NCRs with their ligands on tumor or virus infected cells without the need
for prior antigen recognition is one of the main mechanisms that allow a rapid clearance of
target cells.The three known NCRs, NKp46, NKp44, and NKp30, comprise a family of germ-
line encoded Ig-like trans-membrane (TM) receptors. Until recently, NCRs were thought to
be NK cell specific surface molecules, thus making it possible to easily distinguish NK cells
from phenotypically similar cell types. Moreover, it has also been found that the surface
expression of NKp46 is conserved on NK cells across mammalian species. This discovery
allowed for the use of NKp46 as a reliable marker to identify NK cells in different animal
models, a comparison that was not possible before due to the lack of a common and com-
prehensive receptor repertoire between different species. However, several studies over
the recent few years indicated that NCR expression is not exclusively confined to NK cells,
but is also present on populations of T as well as of NK-like lymphocytes. These insights
raised the hypothesis that the induced expression of NCRs on certain T cell subsets is
governed by defined mechanisms involving the engagement of the T cell receptor (TCR)
and the action of pro-inflammatory cytokines. In turn, the acquisition of NCRs by T cell
subsets is also associated with a functional independence of these Ig-like TM receptors
from TCR signaling. Here, we review these novel findings with respect to NCR-mediated
functions of NK cells and we also discuss the functional consequences of NCR expression
on non-NK cells, with a particular focus on the T cell compartment.
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INTRODUCTION
Natural Killer cell Receptors (NKRs) comprise several trans-
membrane (TM) inhibitory and activating molecules that regulate
natural killer (NK) cell function and homeostasis. Within this
group are Killer-cell-Ig-like-receptor (KIR), lectin type receptors
as well as Natural Cytotoxicity Receptors (NCRs). The ability of
NK cells to perform effector functions is determined by a deli-
cate balance of signals received from these receptors. Activating
NKRs, including NCRs, are germ-line encoded proteins, which
allow NK cells, differently from T cells, to respond to harm-
ful cells without prior antigen sensitization (Vivier et al., 2011).
Although most of the NKRs were originally identified on NK
cells, they have also been reported as constitutively expressed by
some T lymphocyte populations (Raulet et al., 2001; Lanier, 2005).
Nonetheless, it was thought that NCRs, and in particular NKp46
and NKp30, were present exclusively on resting NK cells (Pessino
et al., 1998; Pende et al., 1999; Moretta et al., 2002). Recent data
has revealed, however, that NCRs are expressed on other popu-
lations of cells, such as T cells and NK-like cells (Meresse et al.,
2006; von Lilienfeld-Toal et al., 2006; Stewart et al., 2007; Walzer
et al., 2007b; Tang et al., 2008; Bensussan et al., 2011; Correia
et al., 2011; Hudspeth et al., 2012). In particular, the functions
of NCRs on certain T cell subsets appears to mirror the ones of
the NCRs expressed on NK cells. In this regard, the main working
hypothesis is that T lymphocytes employ these activating receptors
to circumvent antigen-restricted responses, thus allowing them
to respond rapidly against dangers to the host. Alternatively, it
has also been speculated that the expression of NCRs may rep-
resent a marker for those T cells that have undergone chronic
activation and have lost immune tolerance (Meresse et al., 2006;
Stewart et al., 2007; Correia et al., 2011). Here, we review the
recent findings regarding the phenotypic distribution of NCRs on
non-NK cell types and their functional consequences on immune
responses.
IDENTIFICATION AND MOLECULAR STRUCTURE OF NCRs
The identification and cloning of three NCRs, NKp46, NKp30, and
NKp44, was achieved in the late 1990s and revealed that NKp46
and NKp30 are expressed by NK cells freshly purified from periph-
eral blood, whereas NKp44 is induced upon NK cell activation
(Sivori et al., 1997; Pessino et al., 1998; Vitale et al., 1998; Cantoni
et al., 1999).
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Natural cytotoxicity receptors are type I TM receptors that,
unlike T cell receptors (TCRs) and immunoglobulins, do not
undergo any somatic recombination [i.e.,V(D)J genetic rearrange-
ments] in order to become functionally active. Moreover, the char-
acterization of NCRs using crystallography has revealed that they
are structurally quite different from each other, despite belonging
to the same group of receptors and performing similar functions
(Cantoni et al., 2003; Foster et al., 2003; Li et al., 2011). The NKp46
gene (NCR1) encodes for an Ig-like receptor, which contains two
extracellular Ig domains, a type I TM domain and a short cytoplas-
mic tail. Unlike NCR1, the genes encoding for NKp30 and NKp44,
NCR2 and NCR3, give rise to type I TM proteins with only one
extracellular Ig domain. The TM regions of all three NCRs are
coupled with adaptor molecules given their lack of inherent sig-
naling motifs (Figure 1). Following the ligation of NCRs with
their putative ligands, these adaptor molecules allow for intracellu-
lar activating signaling through immune-receptor tyrosine-based
activating motifs (ITAMs). Notably, the cytoplasmic domain of
NKp44 contains an immunoreceptor tyrosine-based inhibitory
(ITIM) motif that, in contrast to ITAM motifs, impart negative
signals and are contained within inhibitory receptors such as KIRs
(Pessino et al., 1998; Vitale et al., 1998; Cantoni et al., 1999; Pende
et al., 1999; Campbell et al., 2004).
NCR FUNCTIONAL CORRELATES ON NK CELLS
NCR-MEDIATED ELIMINATION OF TUMOR-TRANSFORMED CELLS
Natural cytotoxicity receptors were originally identified as NKRs
that have the ability to mediate the killing of tumor-transformed
cells (Sivori et al., 1997; Pessino et al., 1998; Vitale et al., 1998;
Pende et al., 1999; Moretta et al., 2001). Indeed, it soon became
clear that NCRs are able to arm NK cells with the ability to respond
robustly and with high efficiency against tumor-transformed cells.
While the killing of certain tumor cells by NK cells sometimes
involves more than one NKR, the lysis of other tumor cells can be
entirely mediated by NKp46 or NKp30 or NKp44, thus highlight-
ing the unique ability of each one of the three NCRs to individually
trigger NK cell cytotoxicity (Moretta et al., 2001). Other factors
determining NK cell-mediated lysis of tumor cells are the pres-
ence of NCR ligands on the surface of targets (Byrd et al., 2007;
Halfteck et al., 2009) as well as the surface levels of NCRs on NK
cell surface (Sivori et al., 1999). In fact, NKp44 is expressed only
on activated circulating NK cells both in vitro and in vivo, while
the stimulation of NK cells with cytokine such as IL-2 increases
the constitutive expression and the cytolytic potential of NKp46
and NKp44 (Moretta et al., 2001; Mavilio et al., 2003). In addi-
tion and confirming the key role of NK cells in the clearance of
certain tumors in vivo (Smyth et al., 2002), several studies have
FIGURE 1 | Structure of NCRs. Molecular structures of NKp46, NKp30, and
NKp44 including the presence and the number of extracellular domains, the
type of adaptor molecules (to the right to each NCR), the chromosomal
location, the species in which a functional gene is present, and family of
receptors homologous to the respective NCR. Abbreviations: KIR, killer
immunoglobulin receptor; LIR, leukocyte immunoglobulin-like receptor; ITAM,
immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor
tyrosine-based inhibition motif.
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demonstrated that the absence of NKp46 results in an impaired
eradication of certain tumors, such as lymphoma and melanoma
(Gazit et al., 2006; Halfteck et al., 2009; Lakshmikanth et al., 2009;
Glasner et al., 2012).
NCR-MEDIATED CLEARANCE OF CELLS INFECTED BY PATHOGENS
Along with their ability to eliminate tumor-transformed cells,
NCRs have also been implicated in the control and elimination of
several pathogens. In fact, NKp46 has been shown to be required
for the eradication of bacteria and virus infection in vivo, since NK
cells were unable to recognize and eliminate infected cells express-
ing NKp46 ligands in NKp46-deficient mice inoculated with
influenza virus (Gazit et al., 2006). Another representative exam-
ple of the central role of NCRs in the control of virus infection was
shown in an in vitro model of human cytomegalovirus (HCMV)
infection (Magri et al., 2011). In the present study, authors demon-
strated that the clearance of HCMV-infected monocyte derived
dendritic cells (MDDCs) is associated with the down-modulation
of self major histocompatibility complex of class I (MHC-I)
molecules, whose interactions with inhibitory NK cell receptors
(iNKRs) normally switch off NK cell effector functions. The lack
or decreased engagement of iNKRs with their putative self-MHC-I
ligands makes it possible for NK cells to recognize and kill harm-
ful HCMV-infected MDCCs through the direct recognition of
a self-encoded NKp46 ligand on these target cells (missing self
hypothesis) (Ljunggren and Karre, 1990).
Similarly, NKp46 has also been demonstrated to play a key
role in the recognition and clearance of Streptococcus pneumoniae.
Indeed, NKp46-deficient mice were reported to have reduced NK
cell activation and interferon-γ (IFN-γ) production during the
course of early S. pneumoniae infection in the lungs. In contrast,
NKp46-expressing wild type mice appear to be endowed with
potent alveolar macrophage responses as compared to NCR1-
deficient mice. This result correlates with the higher fraction of
NKp46 ligand on lung macrophages in NCR1-expressing mice
that are also equipped with better phagocytic activity compared
to that of macrophages with lower or negative surface levels of
NKp46 ligands (Elhaik-Goldman et al., 2011).
Natural cytotoxicity receptors have also been shown to play
an important role in the pathogenesis of HIV-1 infection. First,
our group identified a pathologic expansion of a subset show-
ing an abnormal receptor repertoire that greatly impairs NK cell
cytolytic and immune-regulatory functions (Fauci et al., 2005;
Brunetta et al., 2010). In particular, the expression of NKp46 and
NKp30 is remarkably reduced on circulating and freshly puri-
fied NK cells from HIV-1 infected patients with high levels of
chronic viremia, and this is directly associated with the decreased
ability of NK cells to lyze NCR-ligand-positive tumor cell lines
(De Maria et al., 2003; Mavilio et al., 2003, 2005). In addition to
the impairment in NK cell function, it is well known that HIV-1
viremia induces a CD4pos T cell depletion that leads to immun-
odeficiency and correlates with disease progression. However, it
has also been reported that the disappearance of the majority
of CD4pos T cells during infection are not productively infected
with HIV-1 (Alimonti et al., 2003). One possible explanation is
that these uninfected CD4pos T cells are eliminated through a
mechanism not directly linked to viral replication. In this regard,
our group demonstrated both in vitro (Ward et al., 2007) and
ex vivo (Fogli et al., 2008) that HIV-1 replication can induce
the expression of ligands for NKp46, NKp30, and NKp44 on
uninfected CD4pos T cells. The fact the HIV-1 is able to specif-
ically induce the expression of NCR ligands on uninfected cells
has also been confirmed by another study demonstrating that
a highly conserved motif of HIV-1 gp41 envelope protein can
induce the expression of NKp44 ligand on uninfected CD4pos T
cell blasts and render these cells susceptible to NK cell-mediated
killing via NKp44 (Vieillard et al., 2005). Indeed, in a model
of simian human immunodeficiency virus (SHIV) infected non-
human primates, immunization with the 3S gp41 peptide has been
shown to prevent the expression of NKp44 ligand on CD4pos T
cells, thus lowering the depletion of these cells (Vieillard et al.,
2008).
On the other hand and according to the aforementioned “miss-
ing self hypothesis” (Ljunggren and Karre, 1990), NK cells should
be able to recognize and kill CD4pos HIV-1 infected cells, which
have been shown to selectively down-modulate self human leuko-
cyte antigens allele A and B (HLA-A and -B) (Ward et al., 2007;
Fogli et al., 2008). In this regard, we have to also take into account
that HLA-C and HLA-E alleles are not down-regulated on CD4pos
T cells upon infection with HIV-1 and this would protect, at least in
part, HIV-1 infected cells from NK cell killing. However, not all cir-
culating NK cells express specific inhibitory receptors recognizing
HLA-C and -E. In particular, only a fraction of the main cyto-
toxic CD56dim/CD16pos NK cells express NKG2A or LIR1/ILT2.
Therefore, other mechanisms are required to explain the impaired
NK cell cytolytic activity against autologous, endogenously HIV-1
infected CD4pos T cells. We have shown that this phenomenon is
also due to the defective surface expression and function of NCRs,
while the residual NK cell-mediated killing of HIV-1 infected cells
occurs mainly through NKG2D, the only main activating NK cell
receptor whose surface expression is not affected by high levels
of plasma viremia (Mavilio et al., 2003, 2005) and whose ligands
on HIV-1 infected cells have been demonstrated to be induced by
ongoing viral replication (Ward et al., 2007; Fogli et al., 2008). All
of the above-mentioned experimental evidence highlight the key
contribution of NCRs to the physiopathology of HIV-1 infection,
since their impaired functions greatly affect the clearance of the
virus and contribute to the related acquired immune-deficiency
and progression to AIDS.
NCR-MEDIATED REGULATION OF IMMUNE HOMEOSTASIS
It has recently become clear that the function of NCRs is not only
in the induction of NK cell lysis of harmful tumor-transformed
or infected cells, but they also play a major role in regulating the
homeostasis of immune responses. In the context of the recently
disclosed cross-talk between NK cells and autologous dendritic
cells (DCs), NKp30 is able to edit the maturation of DCs by killing
unresponsive, aberrant, or immature DCs (iDCs) and by spar-
ing properly matured DCs (mDCs) that can then migrate to the
secondary lymphoid organs. The final outcome of this NKp30-
mediated interaction is the coordination and optimization of a
correct DC priming in order to develop an antigen-specific T cell
response. The engagement of NKp30 on NK cells in the context
of their interaction with autologous DCs highly contributes to
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establish important links between innate and adaptive immune
responses through a process that requires both NK cell-DC cellular
contacts and secretion of specific cytokines (Ferlazzo et al., 2002;
Gerosa et al., 2002; Moretta, 2002; Cooper et al., 2004; Raulet, 2004;
Degli-Esposti and Smyth, 2005; Walzer et al., 2005). Our group
reported that NK cell-DC interactions are markedly impaired and
partially disrupted during the course of chronic and active HIV
infection due to the decreased expression and impaired function
of NKp30 on NK cells. This defect leads to an abnormal matura-
tion of DCs that, upon migration to secondary lymphoid organs,
are defective in priming an optimal HIV-1 specific T cell immune
response and also contribute to spread the infection (Mavilio et al.,
2006; Brunetta et al., 2010).
Natural cytotoxicity receptors have also been shown to be
involved in the NK cell killing of polymorphonuclear neutrophils
expressing NKp46 ligand. Indeed, co-culture experiments revealed
that human NK cells could trigger caspase-dependent neutrophil
apoptosis in a cell contact-dependent manner, which is medi-
ated by NKp46 as well as the Fas/Fas ligand pathway (Thoren
et al., 2012). To further support their findings in vitro, the authors
used an in vivo human model of neutrophil extravasation where
NKp46pos NK cells were seen to infiltrate areas of cutaneous
inflammation, populated by neutrophils. Additionally, the authors
noted a positive correlation between the appearance of NKp46pos
NK cells and neutrophil apoptosis. This study provides evidence
that apoptosis mediated by NKp46 on NK cells assists in the ter-
mination of inflammation by eliminating effector cells to avoid an
unwanted immune response.
As described above, NCRs have long been assumed to act solely
as activating receptors for NK cells and to serve as a key com-
ponent in the innate arm of the immune response. However,
in a recent report NKp46 was ascribed to have quite a differ-
ent immune-regulatory function on NK cells (Narni-Mancinelli
et al., 2012). This was demonstrated in a mouse model (Noè mice)
bearing an NKp46 loss-of-function mutation, which resulted in
a hyper-responsive NK cell response and in an increased resis-
tance to murine CMV (MCMV) and influenza virus infections.
The increased NK cell activity was associated with a decreased
ability to prime T cells during infection, which resulted in a
diminished memory T cell response after antigen challenge. Inter-
estingly, expression of the transcript levels for Helios, a member
of the Ikaros transcription factor family genes, inversely corre-
lated with the presence of NKp46. Reintroducing NKp46 into
the loss-of-function mouse strain restored mRNA levels of Helios
and was critical for the subsequent development of optimal anti-
viral and antibacterial T cell responses. Taken together, these
data suggest that NKp46, other then being an activating recep-
tor triggering NK cell cytotoxicity, is also endowed with regulatory
functions which ultimately lead to a correct priming of antigen-
specific adaptive immune responses against virus infections. While
these results are certainly innovative and disclose an unpredicted
NKp46-mediated NK cell functional correlate, we have to take
into account, as also stated by the same authors, that this NCR
is constitutively present on the surface of a CD3pos T cell sub-
set in the spleen of Noè mice and that the NKp46 mutation
significantly affects its expression on this T cell population as
well.
NCR-MEDIATED PRODUCTION OF PRO-INFLAMMATORY CYTOKINES
In addition to their ability to induce cytotoxicity, NCRs can also
mediate the production of pro-inflammatory cytokines by NK
cells. Early experiments showed that cross-linking of NKp46 and
NKp44 resulted in the production of IFN-γ and tumor necrosis
factor-α (TNF-a) (Sivori et al., 1997; Vitale et al., 1998). It is well
known that the production of these pro-inflammatory cytokines is
essential for the clearance of bacterial and viral pathogens as well as
in the modulation of immune responses (Pfeffer, 2003; Schroder
et al., 2004). Among the several examples of the functional conse-
quence of NCR-mediated cytokine production, there is the ability
of NKp30 expressed on NK cells to bind its ligand on the surface of
iDCs. This cellular interaction leads to the NK cell production of
several cytokines such as IFN-γ and TNF-α which, in turn, trigger
autologous DC maturation (Moretta, 2002). In particular, it has
been shown that different isoforms of NKp30 are able to elicit the
production of different cytokines by NK cells in response to inter-
actions with autologous iDCs (Delahaye et al., 2011). Isoforms of
NKp30 can arise due to mutations in exon 4, which results in the
production of three splice variants of NKp30: the isoforms a, b, and
c containing distinct intracellular domains. While the binding of
NKp30a and NKp30b with their putative ligands on iDCs results in
the production of high amounts of IFN-γ and TNF-α, the NKp30c
isoform does not induce the NK cell synthesis of pro-inflammatory
cytokines. Instead, NKp30c interaction with its ligands on iDCs
results in the production of the anti-inflammatory cytokine IL-
10. Moreover, the engagement of NKp30c, unlike NKp30a and
NKp30b splice variants, is also associated with a reduced abil-
ity of NK cells to produce IFN-γ and to kill target cells. In line
with this, it has also been demonstrated that the cross-linking of
these three different isoforms induces distinct signals in NK cells
since NKp30a and NKp30b, but not NKp30c, are coupled with
CD3ζ, the ITAM-bearing adaptor protein required for activating
downstream signaling. The correct functions of NKp30 isoforms
within NK cell-DC interactions contributes to regulate the opti-
mal maturation of DCs in the context of the NK cell-mediated
editing of these antigen presenting cells (APCs). In fact, only those
DCs that fail to undergo a correct maturation are then recognized
by NK cells and killed via activating isoforms of NKp30 (Dela-
haye et al., 2011). Although several splice variants of NKp46 and
NKp44 have been reported, a functional characterization of these
NCR isoform has not yet been performed. It will be of interest to
determine whether variants of NKp46 and NKp44 are expressed
on primary human lymphocytes and if such isoforms, similarly to
what has been observed for NKp30c, have different effects on NK
cell functions.
Finally, the binding of NKp46 to its ligand expressed on the sur-
face of cells infected with HCMV and Fusobacterium nucleatum
has also been shown to trigger the production of inflammatory
cytokines (Magri et al., 2011; Chaushu et al., 2012).
OTHER FUNCTIONS OF NCRs
An abundant presence of NCRs has been recently described in
the human decidua where they are known to play an important
and unexpected role during pregnancy. Indeed, the human uterine
mucosa during pregnancy is comprised of an unusually high fre-
quency of NK cells (up to 40% of total immune cells) (Hanna et al.,
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2006). Different from circulating NK cells (Moretta et al., 2001),
decidual NK cells constitutively express NKp44 and this is likely
due to their constant exposure in the decidua with activating recep-
tors and pro-inflammatory cytokines. Indeed, NK cells from the
decidua express high amounts of the early activation marker, CD69
(Michael and Lotze, 2010). The function of NCRs on NK cells from
the decidua is unique, since their interactions with putative ligands
on the surface of trophoblasts induces the synthesis by NK cells of
the angiogenic factors vascular endothelial growth factor (VEGF),
placental growth factor (PLGF), chemokines interferon-inducible
protein-10 (IP-10), stromal cell-derived factor-1 (SDF-1), and IL-
8. In turn, the NCR-mediated secretion of these proteins is able
to regulate trophoblast invasion during pregnancy and induce
angiogenesis in the decidua (Hanna et al., 2006; Vacca et al., 2008).
In contrast to the regulatory and “peaceful” role of NCRs in
ensuring a correct homeostasis of human female genital tract
during pregnancy, it has also been demonstrated that NCRs are
involved in the physiopathology of autoimmunity. In fact, the
induced expression of an NKp46 ligand by pancreatic β cells
correlates with high levels of NKp46pos NK cells infiltrating the
pancreatic islets during the course of type 1 diabetes. The bind-
ing between NKp46 and its ligands has been shown to induce
a remarkable NK cell degranulation that, in turn, contributes
to the destruction of pancreatic islets. The important role that
NKp46 plays an in the pathogenesis of autoimmune diabetes is
also confirmed by the fact that the NK cell-mediated depletion
of pancreatic islets is greatly reduced if not abrogated in NKp46-
deficient mice or after injecting soluble NKp46 in wild type mice
(Gur et al., 2010).
Natural cytotoxicity receptors have also been shown to be
involved in the pathogenesis of periodontitis, a condition caused
by F. nucleatum and Porphyromonas gingivalis, which results in
tooth loss. Although it is clear that these bacteria initiate periodon-
titis, the progression of the disease is actually caused by the hosts’
innate and adaptive immune systems through the production of
inflammatory cytokines. In this context, it has been reported that
NCRs play a role in the exacerbation of periodontal disease in a
mouse model of periodontitis, since F. nucleatum is able to directly
bind NKp46 on NK cells that, in turn,produce high levels of TNF-α
(Chaushu et al., 2012).
REGULATION OF NCR EXPRESSION
Once it became evident that NCRs harness a remarkable poten-
tial as targets in the development of therapies for the clearance of
tumor-transformed cells, researchers became interested in devel-
oping methodological approaches to implement and optimize the
expression of NCRs on NK cells. As pointed out earlier, NKp46 and
NKp30 are constitutively expressed on NK cells, whereas NKp44
is induced upon NK cell activation with IL-2 (Cantoni et al., 1999;
Moretta et al., 2001). It has been subsequently shown that surface
expression of NKp44 is also increased using other γc cytokines
such as IL-15 (de Rham et al., 2007). Interestingly, IL-21 can pre-
vent the induction of NKp44 by either IL-2 or IL-15 due to its
ability to down-modulate DAP-12, an adaptor molecule required
for signaling and stable surface expression of NKp44 (Campbell
et al., 2004; de Rham et al., 2007). In contrast, NCRs are down-
modulated in vitro by TGF-β, but not after incubation with either
IL-10 or IL-4, which suggests that anti-inflammatory cytokines
may have an important role in the suppression of NCR-mediated
NK cell responses (Castriconi et al., 2003). Moreover, a decrease
in the surface expression of NCRs has also been detected on NK
cells from patients with chronic immune activation occurring dur-
ing several diseases such as HIV-1 infection and tumors (Costello
et al., 2002; De Maria et al., 2003; Mavilio et al., 2003; Fauriat et al.,
2007; Garcia-Iglesias et al., 2009). The differential modulation of
NKp46, NKp30, and NKp44 in various settings both in vitro and
in vivo implies that NCRs are not entirely redundant and can
be specifically modulated to eliminate unwanted and dangerous
cellular targets in the context of distinct immune responses.
In contrast to the vast amount of data available regarding the
cell surface modulation of NCRs, there is a relative paucity of infor-
mation with respects to their transcriptional regulation. Some
insight has, however, been provided by the investigation of the
mechanisms of NKp46 expression regulation. Extensive examina-
tion of the presence of mRNA for NCR1 in various mouse and
human cells has revealed that this gene is constitutively expressed
in NK cells, which suggests the existence of a transcriptional con-
trol of NKp46 expression (Pessino et al., 1998; Lai and Mager,
2012). Indeed, two regions upstream of the NCR1 gene have been
identified in mice and humans. They contain promoter activi-
ties and control the expression of NKp46 on NK cells (Walzer
et al., 2007a; Lai and Mager, 2012). It was shown that one of these
regions contains an essential promoter, which includes a runt-
related transcription factor (RUNX) motif. The second region
was identified as a promoter enhancer with a RUNX and an
ETS binding motif. Truncation mutants revealed that the essen-
tial promoter confers global expression of NCR1, while the region
containing the enhancer was found to have either enhancer activ-
ity or suppressor activity depending on the cell type. Indeed, this
enhancer region augmented the essential promoter activity when
expressed in NK cells, while it suppressed promoter activity when
expressed in cells other than NK lymphocytes. The regulation of
the enhancer in regard to NKp46 gene expression in NK cells is
dependent on RUNX3, whereas it has no effect on the essential pro-
moter. While the promoter element also contains an ETS binding
motif, its ability to regulate NKp46 expression has not yet been
disclosed.
LIGANDS FOR NCRs
Over the past decade, intensive and important work has been
performed in order to elucidate the identity of NCR ligands.
Unlike other NK cell receptors, which in general bind self-MHC
and MHC-related proteins, NCRs appear to recognize a different
set of ligands that include pathogen-derived molecules as well as
non-MHC self-molecules expressed on stressed cells.
PATHOGEN COMPONENTS AS NCR LIGANDS
Several reports have described that the hemagglutinin (HA) pro-
tein of the influenza and vaccinia virus can bind NKp46 and
stimulate NK cells to lyse virus infected cells (Mandelboim et al.,
2001; Jarahian et al., 2011). While vaccinia virus HA can act to
stimulate NK cell activity through NKp46, this viral glycoprotein
was also shown to inhibit NK cell function through the binding
of NKp30. Additionally, the recognition of Sendai and Newcastle
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viruses can also occur through NKp44 and NKp46 (Mandelboim
et al., 2001; Arnon et al., 2005; Jarahian et al., 2011).
Natural killer cell activation by pathogens via NCRs appears not
only to be limited to viruses but it has also been reported for intra-
cellular bacteria and parasites. The Duffy binding-like 1α domain
within the Plasmodium falciparum erythrocyte binding protein
of the malaria parasite was shown to bind and activate NK cells
through NKp46 and NKp30 (Mavoungou et al., 2007). Moreover,
NK cell recognition of Mycobacterium tuberculosis via the host
protein vimentin expressed on the surface of infected monocytes
was also reported to occur through NKp46 (Garg et al., 2006).
While many pathogens have been shown to activate NK cells
through NCRs, a component of the HCMV virus, pp65, was
reported to inhibit NK cell lysis of HCMV-infected cells as well as
to impair NK cell-mediated killing of susceptible tumor cells and
iDCs through the NKp30 receptor. The mechanism explaining the
HCMV-induced inhibition of NK cell effector functions is based
on the ability of pp65 to promote the dissociation of NKp30 from
the CD3ζ chain, an ITAM-bearing adaptor molecule required for
activating the downstream signal of NKp30 following the binding
with its putative ligand (Pende et al., 1999; Arnon et al., 2005).
SELF-MOLECULES AS NCR LIGANDS
Several studies have revealed that ligands for NCRs are not only ele-
ments from pathogens, but include self-derived molecules as well.
The identification of these molecules on tumor and/or stressed
cells is of vital importance to understand their interactions with
NK cells and for the development of novel cancer therapies. In
this regard, it has been described that several putative endogenous
ligands expressed by tumor cells are capable of eliciting an NK cell
response through NCRs.
One of the first self-molecules identified to interact with
NKp30 is the Human Leukocyte Antigen-B-Associated Transcript
3 (BAT3) (Pogge von Strandmann et al., 2007). The expression of
this molecule on tumor cell surface triggers NK cell killing and pro-
duction of TNF-α and IFN-γ following the engagement of NKp30.
The stimulatory ability of BAT3 has also been confirmed in vivo by
experiments showing that peripheral blood NK cells injected into
nude mice are not as efficient in clearing tumors when a blocking
antibody to BAT3 was administered. It was subsequently demon-
strated that even the killing of iDCs by autologous NK cells occurs
through the secretion of BAT3 by iDCs in response to non-lethal
heat shock. Therefore, the expression of BAT3 on iDCs plays a key
role in the NK cell editing of autologous DC maturation given
that the presence of this NKp30-ligand on the surface of iDCs can
lead to the clearance of aberrant or improperly mDCs (Simhadri
et al., 2008). Moreover, the presence of BAT3 was shown not to
affect the binding of HCMV pp65 to NKp30, thus indicating that
NKp30 contains more than one epitope for the recognition of
multiple ligands.
Another important study identified a new member of the B7
receptor family, B7–H6, as another ligand for NKp30 (Brandt
et al., 2009). B7–H6 is present on cell surface of both primary
tumors and tumor cell lines, while it is not expressed by healthy
nor stressed cells. The presence of B7–H6 on the surface of tumor
cells makes them susceptible to NKp30-mediated killing by NK
cells, while the binding of B7–H6 with NKp30c, the inhibitory
isoform of NKp30, induce NK cells to produce IL-10. The ability of
NKp30c isoform to inhibit NK cell functions has also been shown
to affect the clinical outcome of tumors, since the expression of
this splice variant on NK cells correlates with a poor prognosis of
gastrointestinal sarcoma (Delahaye et al., 2011).
An additional reported ligand for both NKp30 and NKp46 is
the membrane associated heparan sulfate proteoglycan (HSPG),
which is expressed on the surface of various tumor cells (Bloush-
tain et al., 2004). However, whether this molecule is a true binding
partner for NKp30 remains controversial (Warren et al., 2005).
This notwithstanding, it has been reported that the presence of
three basic amino acids within the exposed regions of the distal
portion of the Ig domain of this NCR is essential for the binding
of HSPG to NKp46 (Zilka et al., 2005; Ito et al., 2011). However,
mutations of these three amino acids did not affect the binding of
NKp46 to influenza virus HA indicating that NKp46, like NKp30,
contains more than one binding site for the recognition of multiple
ligands (Ito et al., 2011).
NKp44 has been shown to interact with the proliferating cell
nuclear antigen (PCNA), which is commonly expressed by tumor
cells and recruited to cell synapses with NK lymphocytes. In con-
trast to what has been observed for NKp46 and NKp30 ligands,
the ligation of NKp44 with PCNA strongly inhibits both NK cell
cytotoxicity and IFN-γ production (Rosental et al., 2011). The
PCNA-mediated inhibition of NK cell function has been associ-
ated with the unusual presence of the inhibitory ITIM motif within
the intracellular domain of NKp44 (Moretta et al., 2001).
EXPRESSION AND FUNCTION OF NCRs ON IMMUNE CELLS
OTHER THAN NK CELLS
Reviewing the recent literature, one can find many papers describ-
ing the expression of NCRs on non-NK or NK-like cell populations
(Figure 2; Table 1). The expression of NKRs on cells other than NK
cells is, however, not a new concept. Indeed, it is well known that
that certain populations of T cells can express several inhibitory
and activating NKRs such as KIRs, NKG2D, CD94/NKG2C (Hay-
day, 2000; Fauci et al., 2005; Parham, 2005; Borrego et al., 2006;
Eagle and Trowsdale, 2007). Nonetheless, for several years the pres-
ence of a shared repertoire of NKRs between NK and non-NK
cells did not include NCRs, whose expression had been originally
described to be NK cell specific (Moretta et al., 2001). The recent
and continued discoveries of NK-like immune cells and, more
specifically, of new lymphoid subsets both in human peripheral
blood and tissues has prompted some researchers to closely inves-
tigate whether NCRs could also be present and be functionally
relevant on such cells.
EXPRESSION OF NCRs ON T LYMPHOCYTES
The original cluster of papers published in the late 1990s (Figure 2;
Table 1) characterizing the phenotype and functions of human
NCRs revealed a highly specific NK cell expression pattern of
these receptors (Sivori et al., 1997; Pessino et al., 1998; Vitale
et al., 1998; Cantoni et al., 1999; Pende et al., 1999; Moretta
et al., 2001). One of the first reports showing the presence of
NCRs on cell types other than NK lymphocytes demonstrated
that in vitro expanded γδ T cell clones from the peripheral blood
could express low levels of NKp44, but not NKp46 or NKp30,
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FIGURE 2 | History of NCRs.Timeline scheme showing and
referencing the distinctive hallmarks of NCRs since the discovery of NK
cells. Of note, although these receptors were first described to play a
key role in triggering NK cell cytotoxicity and cytokine secretions,
several studies lately reported that NCRs are expressed also on non-NK
immune cells.
Table 1 | Distinctive hallmarks of NCRs since the discovery of NK cells.







Human NKp44 IL-3 Inhibition Fuchs et al. (2005)
αβT cell in small
intestinal epithelium
Human NKp44, NKp46 TCR and IL-15 Lysis Meresse et al. (2006)
TCRγδlow CD3neg Mouse NKp46 TCR Unknown Stewart et al. (2007)
Cord blood T cells Human NKp46, NKp44,
NKp30
gc Cytokines NKp30-dependent lysis
and IFNγ production only
Tang et al. (2008)
RORγtpos/IL-22pos Human, mouse NKp46 (mouse),
NKp44 (human)
Unknown Unknown Satoh-Takayama et al.









Correia et al. (2011),
Hudspeth et al. (2012)
NKT leukemia Human, mouse NKp46 TCR and IL-15 Unknown Yu et al. (2011)
only after cell activation (Vitale et al., 1998). Later on, the expres-
sion of several NKRs, including NKp46, has been reported on
human TCR αβ intestinal intraepithelial lymphocytes (IEL) (Jabri
et al., 2000; Meresse et al., 2006). It was then hypothesized that
the gut epithelium could favor the presence and/or the expan-
sion of a population of CD3pos/TCR-αβpos cytotoxic NK-like
lymphocytes expressing several NCRs and other NKRs during the
course of intestinal inflammation in patients affected by celiac
disease. It was subsequently disclosed that IL-15, a cytokine over
expressed in celiac disease, could convert the aforementioned
IELs into lymphokine-activated killers, which can lyse tumor cell
targets in an NKG2D-dependent but TCR-independent manner
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(Meresse et al., 2004). Shortly after, the same group identified
another NKR, NKG2C, as being up-regulated on cytolytic IELs
during active celiac disease. Moreover, the induced expression of
NKG2C was found to be associated not only with cytotoxicity,
but also with cell proliferation, a function generally limited to
the engagement of the TCR (Meresse et al., 2006). In particular,
this study showed that NKG2Cpos cytolytic IELs also express a
great repertoire of NK cell-related genes and receptors, including
NKp46 and NKp44. Interestingly, it was shown that this subset of
cells had a decreased expression of the TCR as compared to the
NKG2Cneg counterpart. The two NCRs expressed were functional
as shown in their ability to induce IFN-γ secretion and degranula-
tion. These results suggested that certain inflammatory/activation
conditions might favor the development/differentiation of non-
NK cell populations (i.e., T cells), which can perform TCR-
independent proliferation as well as NKR-mediated effector func-
tions. Notwithstanding the autonomy of NCRs to drive cytotox-
icity, the acquisition of an NK cell program in CD3pos T cells
from gut associated lymphoid tissues (GALT) appears to be depen-
dent on previous TCR triggering as the ability to up-regulate
NKp46 and NKp44 only occurs in effector T cells. Indeed, the
expanded population of IELs expressing high levels of NCRs in
celiac disease displays a highly restricted TCR repertoire indica-
tive of a naturally occurring oligoclonal expansion (Meresse et al.,
2006).
In line with the hypothesis that NCR induction on T cell surface
follows a previous TCR-dependent cell activation, a population
of “NK-like γδ T cells” expressing low amounts of the γδ TCR
and containing high levels of intracellular CD3ε has been recently
described in a mice (Stewart et al., 2007). These NK-like γδ T
cells, which require the thymus and the recombinant activating
gene 1 (RAG1) protein for their development, were also found
to express several NKRs, such as NK1.1 and NKp46, although
the cross-linking of this NCR does not induce the production of
IFN-γ. In contrast, the production of IFN-γ was observed only
when these cells were stimulated with IL-12 and IL-18. Moreover,
despite the expression of several NKRs, NK-like γδ T cells are not
able to lyse the NK cell-sensitive YAC-1 cell line. Future studies
are required to exactly determine the function of NKp46 on these
cells, but their ability to produce IFN-γ and to express various
NKRs clearly indicates that NK-like γδ T cells may share with
NK lymphocytes similar functional properties. The major current
working hypothesis is that the acquisition of an NK cell program
by these T cells is due to their chronic activation and several pieces
of evidence support this theory. First, these cells express low levels
of the γδTCR, which is characteristic of chronic TCR engagement.
Second, they display a memory T cell phenotype and have a high
responsiveness to IL-15, a cytokine that favors survival of NK and
memory CD8pos T cells. Lastly, it has been shown that NKRs are
highly expressed on CD8pos T cells receiving chronic stimulation
of the TCR, a phenomenon also confirmed by the finding that
acute T cell activation in MCMV infected mice fails to up-regulate
NKp46 on T cells (Walzer et al., 2007a). Taken together, these data
suggest that NK-like γδ T cells are indeed T cells, which acquire
an NK-like program following chronic activation that is capable
of potentially driving NK-like functional outcomes independently
from the engagement of TCR.
In vitro activation with IL-15 has been shown to induce
the expression of NKp46 on human peripheral blood
CD56neg/CD8pos T cells as well as the surface levels of all three
NCRs, with NKp30 being predominant, on T cells purified from
cord blood (Tang et al., 2008; Correia et al., 2009). Among all the
cytokines tested in this study, only IL-7 was unable to induce the
expression of NKp30 on the surface of cord blood T cells. This is
likely due to the fact that the de novo expression of these activating
receptors is linked with cell division. Hence, the relative inability of
IL-7 to induce cellular proliferation, as compared to that of IL-15
and IL-2, might explain the lack of a fully inducible expression of
NCRs via IL-7. Of note, the de novo expression of NCRs is limited
to those cord blood T cell subsets showing a cytolytic pheno-
type (either CD8pos or CD56pos) and this phenomenon is equally
distributed among TCR-αβpos and TCR-γδpos populations. Once
again, these data suggest that certain T lymphocyte populations
are able to acquire an NK-like phenotype following activation,
which endows these cells with the ability to perform NK cell effec-
tor functions without prior antigen-specific sensitization. It is still
unclear, however, what arms cord blood T cells with the ability to
express NCRs after cytokine exposure, especially given the relative
naivety of T cells purified from cord blood. In this regard, it has
also been shown that the capacity to up-regulate NCRs is not a
characteristic generally held by naïve cells as naïve T lymphocytes
from the peripheral blood are not able to express NCRs de novo
using the same cytokine stimuli (Tang et al., 2008). Hence, it is
also possible that the unique microenvironment of the umbilical
cord provides certain populations of T cells with the ability to up-
regulate NCRs and this mechanism renders naïve T cells capable
of responding immediately against potential dangers to the host,
without the need for TCR-mediated antigen recognition.
Our group has recently characterized a population of human
peripheral blood γδ T cells bearing the Vδ1 chain in the vari-
able region of the TCR that can be induced to express de novo all
three NCRs, with NKp30 showing the highest level of expression
(Correia et al., 2011). Although circulating γδ T cells are NCRneg,
we found that the surface levels of NKp30, NKp44, and NKp46
could be induced through the engagement of the TCR in synergy
with cytokine stimulation (i.e., IL-2 or IL-15). These stimuli were
able to induce selectively the expression of NCRs without affect-
ing the surface levels of other NKRs such as DNAM-1, NKG2D,
or 2B4. We observed that the de novo expression of NCRs (and of
NKp30 in particular) correlates with cell proliferation, confirming
once again that the NCR induction is associated with cell activa-
tion and division. In fact, our results indicate that NCR induction
is dependent on both TCR stimulation and the presence of γc
cytokines such as IL-15, which is present at high levels during the
course of several inflammatory conditions (Carroll et al., 2008).
Moreover, the hypothesis that the induced expression of NCRs is
limited to certain populations of T cells carrying a particular TCR
(Jabri et al., 2002; Meresse et al., 2006; Stewart et al., 2007; Yu
et al., 2011) is also supported by our data showing that NCRs can
only be induced on γδ T cells expressing the Vδ1 but not the Vδ2
TCR chain. We also showed that NCRpos Vδ1 T cells have strong
potential to be clinically relevant as tools in adoptive cell transfer
(ACT) immunotherapies, as they are highly cytolytic against pri-
mary leukemia cells and against several tumor cell targets resistant
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to the lysis by Vγ9Vδ2 T cells. Moreover, we also demonstrated
that these NCRpos Vδ1 T cells are able to inhibit HIV viral replica-
tion, through the NKp30-mediated production of CCL3/MIP-1α,
CCL4/MIP-1β, and CCL5/RANTES (Hudspeth et al., 2012). These
three cc-chemokines are chemotactic proteins produced by cells
of the immune system and are able to inhibit viral replication by
binding CCR5, one of the primary co-receptors that HIV-1 utilizes
for entry into CD4pos T cells (Cocchi et al., 1995; Deng et al., 1996;
Dragic et al., 1996; Feng et al., 1996). Collectively, these recent
studies revealed that the induced expression of NCRs on γδ T
cells from the peripheral blood endows these cells with important
anti-viral and anti-tumor functions.
The importance of chronic activation given by soluble inflam-
matory factors on immune cells can be also assessed by using
mouse models either over-expressing or lacking pro-inflammatory
cytokines that are critical for immune cell stimulation. To this
end, a transgenic mouse model over-expressing IL-15, a cytokine
required for the homeostasis and proliferation of NK and CD8pos
T cells, was recently engineered (Yu et al., 2011). These mice dis-
play a massive expansion of NK, NKT, and CD8pos T cells, but
approximately 30% of them develop either a T cell large granu-
lar lymphocytes (T-LGL) or NK cell leukemia. The leukemic cells
from T-LGL were CD1d restricted and, as such, this disease has also
been defined as NKT cell leukemia. Surprisingly, these malignant
NKT cells express high amounts of NKp46, despite the presence
of only a small fraction of NKp46pos T cells resident in bone mar-
row, spleen, thymus, and peripheral blood of wild type mice. ACT
experiments clearly indicated that these cells do not originate from
their NKp46neg counterparts, but are the result of the expansion
of those small subsets of NKp46pos NKT cells present in blood
and tissues of healthy mice. In line with these results, murine
NKp46pos T lymphocytes were remarkably more responsive to IL-
15 stimulation compared to their NKp46neg counterparts. Low
frequencies of CD1d restricted NKp46 T lymphocytes have also
been found in the peripheral blood from healthy human donors
and, similar to what has been described in mice, they showed an
increased responsiveness to IL-15 as compared to the NKp46neg
NKT cell subset. In patients diagnosed with T-LGL, both the sur-
face expression of NKp46 receptor and transcript levels of NKp46
gene are much higher compared to those of healthy individuals and
their CD1d restricted NKT cells are generally limited to invariant
alpha and beta TCR chains (Yu et al., 2011). Moreover, it was also
shown that NKp46pos NKT cells are even more skewed toward
certain Vβ chains, as compared to their NKp46neg counterparts,
which supports once again the hypothesis that the induced expres-
sion of NCRs is restricted to T cell subsets bearing only specific
rearrangements of TCRs.
Finally, another line of investigation reported that the selective
expression of NCRs on particular T cell subsets might represent a
novel and useful biologic marker to track leukemia-transformed
cells (Bensussan et al., 2011). In fact, it has been observed that
circulating CD4pos leukemia cells in patients affected by Sezary
Syndrome express NKp46, but not NKp30 or NKp44. Sezary Syn-
drome is an aggressive form of CD4pos T cell leukemia primarily
localized in the skin, but with considerable leukemic cell inva-
sions of the lymph nodes and the peripheral blood. In contrast to
the well known activating function of NKp46, it was found this
NCR could function as an inhibitor of the TCR-mediated pro-
liferation of tumor cells through the hampering of CD3ζ chain
phosphorylation.
The flexibility of T cells to acquire NK-like phenotype and func-
tions has also been confirmed by a recent report showing that in the
absence of the transcription factor B-cell lymphoma/leukemia 11B
(Bcl11b), murine immature double negative (DN) thymocytes are
“re-programmed” to express NK cell receptors, to produce IFN-γ
and to efficiently lyse tumor cells in the absence of antigen-specific
stimulus (Li et al., 2010). However, these induced T-to-natural
killer (ITNK) cells were not entirely NK cells as they retained
expression of CD3, T-bet, CD4, and CD8. Interestingly, this study
also demonstrated the plasticity of T cells in the spleen, which
can be re-programmed to ITNK in the absence of Bcl11b. These
results indicate that T cells during development in the thymus as
well as in the periphery are plastic in nature, although it is still
unclear under what circumstances these NK-like T cells arise and
it remains to be determined which T cells within the periphery are
able to be re-programmed in the absence of Bcl11b.
NCR EXPRESSION ON OTHER CELL TYPES
Several studies in the last few years have described unique popu-
lations of tissue-associated CD3neg innate lymphoid cells (ILCs)
expressing NCRs but lacking classical NK cell functions, such as
cytotoxicity and IFN-γ production. ILCs were originally identified
in the murine intestine as NKp46pos cells phenotypically similar to
lymphoid tissue inducer (LTi) cells (Satoh-Takayama et al., 2008).
LTi cells are a specialized subset of cells, which were originally
described in mice as necessary for the proper growth of lymph
nodes and requiring the transcription factor RORγt for their
development (Colonna, 2009). Likewise, NKp46pos LTi cells from
murine intestine express RORγt and were also reported to produce
IL-22 (Satoh-Takayama et al., 2008). IL-22 is a member of the IL-10
family of cytokines and is involved in the repair and maintenance
of mucosal epithelial barriers (Colonna, 2009). Indeed, mice lack-
ing intestinal IL-22pos/NKp46pos/RORγtpos LTi cells were found
to be more susceptible to Citrobacter rodentium bacterial infection
(Satoh-Takayama et al., 2008). IL-22-producing cells expressing
NKp46 and RORγt and with an LTi functional profile have been
also found in human fetal mesenteric lymph nodes, tonsils, and
the intestine as well as in murine cryptopatches (Cupedo et al.,
2009; Luci et al., 2009; Sanos et al., 2009). It has also been reported
that NKp44 is the major NCR expressed on a cell subset purified
from human tonsils that produces IL-22 and expresses RORγt,
which is functionally similar to NKp46pos/CD3neg cells isolated
from mouse Peyer’s patches (Cella et al., 2009).
It has also been found that cell surface density of the NCRs
varies in RORγtpos LTi cells isolated from different mucosal sites.
While the tonsil and intestine contain IL-22pos/RORγtpos LTi cells
expressing high levels of NCRs, the cellular counterpart from
both adult and fetal lymph nodes expresses very little amounts of
NKp44 and NKp46 and do not produce IL-22, but instead contain
transcripts for IL-17a (Hoorweg et al., 2012). These data indicate
that RORγtpos LTi cells represent a unique immune compartment
regulating the homeostasis of mucosa associated lymphoid tis-
sues (MALT) and that the expression of NCRs and production of
cytokines by LTi cells vary according to their tissue distribution.
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Given their shared similarity with NK cells in terms of NCR expres-
sion and absence of surface molecules indicating terminal stages of
cell differentiation, it was first hypothesized that LTi cells might be
immature NK cell precursors. Among the experimental evidence
supporting this thesis, there were the facts that (i) LTi cells lacking
NKp46 could differentiate into cells expressing NKRs (including
NKp46, NKp44, and NKp30), while maintaining LTi functions,
and that (ii) the immature NK cell population purified from fetal
lymph nodes has been found to contain transcripts for RORγt
and IL-22 (Cupedo et al., 2009). However, despite the induction of
NCRs on LTi cells following stimulation in vitro, the cross-linking
of NKp46, NKp30, and NKp44 does not trigger cytotoxicity in LTi
cells and the ligation of NKp46 is not required for the clearance of
C. rodentium infection in mice (Cella et al., 2009; Luci et al., 2009;
Satoh-Takayama et al., 2009). Only recently it has been clarified by
several reports that, although similar in terms of NCR and RORγt
expression, LTi cells and conventional NK lymphocytes belong to
separate lineages and have distinct functional and transcriptional
profiles both in mice and humans (Crellin et al., 2010; Satoh-
Takayama et al., 2010; Vonarbourg et al., 2010; Narni-Mancinelli
et al., 2012; Tomasello et al., 2012).
Finally, NKp44 was also found to be expressed on a small subset
of IFN-α producing plasmacytoid dendritic cells (pDCs) isolated
from human tonsils (Fuchs et al., 2005). Surprisingly, the pres-
ence of this NCR on pDCs is associated with the inhibition of
TLR-7/9 mediated production of IFN-α, in contrast to the well-
established activating function of NKp44 on NK cells (Moretta
et al., 2001). The mechanism involved in the induction of NKp44
on tissue pDCs seems to be IL-3-dependent, as peripheral blood
pDCs are induced to express NKp44 upon incubation with IL-
3. It has been hypothesized that, due to their natural ability to
produce IL-3 and their close proximity to pDCs in the tonsils,
memory CD8pos T cells play a key role in inducing the expres-
sion of NKp44pos pDCs in human tonsils. Detectable surface
levels of NKp44 have been reported on pDCs from lymph nodes,
blood, and malignancies of patients affected by systemic lupus ery-
thematosus (SLE) (Bonaccorsi et al., 2010). Although a possible
association between SLE and IL-3 has never been fully investi-
gated, the reported increased levels of IFN-α in the serum of SLE
patients might be associated with dysfunctions of NKp44pos pDCs
(Gilliet et al., 2008).
FUNCTIONS OF NCRs ON IMMUNE CELLS OTHER THAN NK
CELLS
While the role of the NCRs on some specialized lymphoid subsets
such as ILCs or LTi cells is currently unknown or being debated,
several pieces of evidence indicate that the expression of NCRs
on certain T cell subsets is able to endow them with an NK-
like program (Figure 3). The acquisition of an NK functional
profile by NCRpos T cells might be a consequence of a chronic
activation of these cells, a phenomenon occurring in many human
inflammatory conditions. Subsequently, the engagement of NCRs
might bypass or substitute for the functions of the TCR in order to
activate those intracellular signaling pathways needed for cell cyto-
toxicity, cytokine production, and cell proliferation. This appears
to be a plausible scenario, since it has been shown that the ITAM-
bearing molecules, like those associated with NCRs, can activate
the Src tyrosine kinases, Lck, and Fyn, which are central in the
initiation of TCR signaling pathways (Vivier et al., 2004).
The novel concept of NCRs representing an alternative path-
way either substituting or synergizing with TCR signaling might
open several new insights in regard to our knowledge of immune
responses against tumors and pathogens. As previously stated,
all experimental evidence collected so far has shown that very
small frequencies of NCRpos T cells are naturally resident in tis-
sues and peripheral blood of both human and mice. Nevertheless,
it has become evident that several activation stimuli, both TCR-
dependent and independent, are able to establish pathways for
the expansion of NCRpos cells or for the de novo induction of
NCRs on T cells with certain TCR rearrangements. One could
speculate that these T cells with particular TCRs might be pre-
programmed to express NCRs, an event that could occur in
the thymus. Post-thymically, TCR-dependent mechanisms would
pave the way for expression of NCRs, which could be induced
under conditions of inflammation wherein IL-15 and IL-2 are in
abundance.
On the other hand, aversion from the normal TCR-mediated
mechanisms of tolerance could have also detrimental effects on
the host. Indeed, stimulation of T cells through germ-line encoded
receptors generally recognizing self-molecules and circumventing
TCR stimulation could likely hinder T cell regulatory mechanisms
and lead to unwanted and aberrant immune responses. As a physi-
ological example of this scenario is represented by the expression of
NCRs on IEL in celiac disease, an autoimmune disorder where the
cytokine IL-15 can drive a pathologic expansion of TCR-αβ IELs
with an NK cell-like phenotype. This mechanism has been pro-
posed to contribute to the destruction of the intestinal epithelium
in patients affected by this disease, although a complete elucida-
tion of these pathogenic mechanisms has not yet been disclosed.
In fact, it is still unknown whether NCR ligands are expressed on
intestinal epithelial cells either constitutively or following inflam-
mation, cell stress, or other stimuli. However, it has been shown
that the expression of MHC-class-I chain-related molecules A and
B (MICA/B) and non-classic HLA-E (i.e., the ligands of the C-
type lectin NKG2D and NKG2C receptors, respectively) is indeed
induced by inflammation and cellular stress, which also repre-
sent the main triggers for the expansion and activation of NCRpos
IELs (Groh et al., 1998; Meresse et al., 2004, 2006). Furthermore,
NCRpos T cells have the potential to become malignant under
certain conditions (Yu et al., 2011), thus indicating that NCRs
could serve as biological markers of immune dysregulation and/or
potential leukemic transformation.
On the contrary however, the hypothesis that NCRpos T cells
might represent a bridge between innate and adaptive immunity
is certainly fascinating as the NCR-mediated and the innate-like
response by T cells against unwanted or dangerous cellular com-
ponents could provide the host with an enhancement of the first
line of defense against pathogens or tumor-transformed cells.
POTENTIAL THERAPEUTIC APPROACHES USING NCRPOS
NON-NK CELLS
The manipulation of NCRs, in particular on γδ T cells, might
represent a promising new tool in ACT immunotherapies. First,
the de novo expression of NCRs (NKp30 in particular) endows
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FIGURE 3 | Phenotypic distribution of NCRs on non-NK cells.
Schematic representation of non-NK cells expressing NKp46, NKp44, and
NKp30. The 4 cell populations were categorized on the basis of cell type
and NCR expressed and the receptor required to induce the NCR
expression is also indicated. Of note, the mechanisms involving the
triggering of TCR and γc cytokines are a common feature of NCR induction
of NCRs on T lymphocytes. Abbreviations: CB, cord blood; IELs,
intraepithelial lymphocytes.
circulating Vδ1 T cells with potent cytolytic ability against primary
leukemia cells resistant to the lysis exerted by the more abundant
Vγ9Vδ2 cell subset (Correia et al., 2011), which have been the focus
of essentially all γδT cell-based cancer immunotherapy trials. This
potential application is in line with the emerging paradigm of γδ
T cells recognizing tumors via innate NK receptors rather than
using the somatically rearranged TCR γδ (Gomes et al., 2010). This
notwithstanding, the anti-tumor function of NKp30pos/Vδ1pos
cells has also a major, albeit indirect, contribution of the TCR.
Indeed, the efficient induction of NKp30 expression on Vδ1pos
cells depends on TCR stimulation; in its absence, γc cytokines
can only induce a very modest up-regulation of NKp30 expres-
sion. Thus, TCR signals are upstream of NKp30-mediated tumor
cell recognition by NKp30pos/Vδ1pos lymphocytes (Correia et al.,
2011). Therefore, we have previously proposed a “two-step” model
for human γδ T cells in which they differentiate and are acti-
vated like prototypic T cells following the engagement of TCR,
but rely essentially on NK receptors (such as NCRs and NKG2D)
for tumor cell recognition. This is consistent with the critical role
described for NKG2D ligands in tumor surveillance by mouse γδ
T cells (Girardi et al., 2001; Strid et al., 2008), and fits the gen-
eral concept of NK receptors being the key molecular recognition
determinants of “oncogenic stress”(Raulet and Guerra, 2009). The
role of NCRs in the potential ACT might be even more relevant
for eradicating several hematological tumors that lack ligands to
NKG2D (Hayday, 2000). From a clinical perspective, the estab-
lishment of a clinical protocol inducing the expression of NCRs
on Vδ1pos cells ex vivo and injecting large numbers of these cells
into patients affected by tumors is feasible. Indeed, we previously
reported that NKp30pos/Vδ1pos cells could be efficiently expanded
from patients affected by B-cell chronic lymphocytic leukemia.
Upon reinfusion, the activation status of the cells could be poten-
tially maintained via administration of low doses of IL-2, which
appears to be sufficient to sustain NKp30 expression (Correia et al.,
2011).
The finding that the NKp30 engagement on in vitro activated
Vδ1 T cells is able to suppress HIV-1 replication through the
NKp30-induced production of CCL3/MIP-1α, CCL4/MIP-1β, and
CCL5/RANTES also reveals new and important insights for under-
standing the role and for manipulating the functions of γδ T cells
during HIV-1 disease. Indeed, HIV-1 infection is characterized by
a great expansion of Vδ1 T cells (Autran et al., 1989; Hinz et al.,
1994; Boullier et al., 1995; Poles et al., 2003) and by chronic inflam-
mation (Appay and Sauce, 2008). In such conditions, activated and
expanded Vδ1 T cells producing cc-chemokines might contribute
to the control of viral replication. This phenomenon is likely to
be even more relevant in mucosal tissues, given that intestinal
and cervical mucosae, where Vδ1 T cells are naturally resident in
high frequencies (Hayday, 2000), are two important gates of HIV-
1 entry. In this context, NKp30pos Vδ1 T cell-mediated control
of viral replication might play an important role in restraining
the establishment of viral reservoirs and in limiting the levels of
mucosal and systemic inflammation generated by the pathologic
translocation of microflora in the lamina propria and mesenteric
lymph nodes following the massive depletion of mucosal CD4pos T
cells in acute and highly viremic stages of HIV-1 infection (Brench-
ley et al., 2006). In line with what was recently demonstrated for
Vγ9Vδ2 T cells in SIV-infected primates (Ali et al., 2009), the estab-
lishment of novel protocols either inducing NKp30 expression on
expanded Vδ1 T cells in vivo or adoptively transferring in vitro
differentiated NKp30pos Vδ1 T cells may be of great therapeutic
value in HIV/AIDS.
CONCLUDING REMARKS
The expression of NCRs on a variety of cell populations other
than NK cells is a relatively new field of research that has changed
the classic paradigm of these receptors being NK cell specific and
opened several new avenues for research and clinical applications.
With regard to T cells, the induction of NCR expression has
been linked to their acquisition of an NK cell-like functional
www.frontiersin.org March 2013 | Volume 4 | Article 69 | 11
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profile, which may be the result of chronic activation or sim-
ply a previous antigen recognition via the TCR. Furthermore,
the expression of NCRs has also been described on populations
of tumor-transformed T cells, which has further validated the
hypothesis that the presence of NCRs follows a prolonged cellu-
lar activation or stress even on pathologic T lymphocytes. In this
context, the use of NCRs as a tool to identify T cells potentially
undergoing leukemic transformation as well as those that have
already undergone transformation presents exciting opportunities
for cancer research, given the lack of markers associated with cer-
tain T cell leukemias. Moreover, the use of NCRs as biomarkers of
T cells that in certain inflammatory and autoimmune conditions
have lost immune tolerance might represent a valuable tool for the
diagnosis of autoimmune disorders. Lastly, in vitro manipulation
to induce NCR expression can arm T cells with potent anti-
tumor and anti-viral activity, thus offering a potentially powerful
therapeutic tool for ACT immunotherapies.
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